The FDA has issued final guidance clarifying its requirements for applications for de novo approval. The update brings the guidance into compliance with the goal of the Medical Device User Fee Amendments of 2017 to accelerate the review process, the agency said.
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.